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Rituximab is a drug used for the treatment of B-cell non-Hodgkin’s lymphoma, and its range of use has expanded to the
treatment of collagen diseases such as idiopathic thrombocytopenic purpura and rheumatoid arthritis. One serious complication
of rituximab use is the reactivation of dormant hepatitis B virus, and prevention of this phenomenon has become an urgent issue.
Thispaperprovidesageneraloutlineoftheproblemthroughananalysisofpatientcasesthatweandothergroupshaveexperienced
to date.
1.Introduction
Rituximab is a human-mouse chimeric monoclonal anti-
body that targets the B-cell CD20 cell surface protein and
has become indispensible for the treatment of B-cell non-
Hodgkin’s lymphoma [1–3]. however, Complications in the
formofsevereviralinfectionshavebeenobserved,andmeth-
ods to counter these infections are presently being evaluated
[4–7]. Reactivation of hepatitis B virus (HBV) is one such
complication. Prior to the introduction of rituximab, reacti-
vation of HBV was a major complication of chemotherapy-
induced immunosuppression [8–20]. The events leading to
HBV reactivation during rituximab/chemotherapy combi-
nation treatment have been reported by various groups,
as have the eﬀects of preventive administration of the
nucleoside analogue lamivudine on the suppression of HBV
reactivation [21–33]. However, a number of issues remain
to be determined, such as the level of HBV resistance to
lamivudine, the optimal lamivudine administration period,
and even whether or not lamivudine is the best preventive
drug to use. HBV reactivation may result in a number of
serious outcomes, including death from hepatitis [23–37].
Additionally, even in the event that hepatitis is prevented,
possible problems in subsequent lymphoma treatment or
in anticipated outcomes may arise, such as lymphoma
recurrence or shortened survival prognosis. In this paper
based on studies from various groups, we explored issues
in preventive nucleoside analog administration, including
optimal administration period and the utility of concurrent
use of these drugs. The discussion includes a compilation
of our results on preventive administration of nucleoside
analogs in HBs antigen- (HBsAg-) positive cases, which were
accrued from the debut of rituximab in Japan in 2002 to
December 2008.
2. HBV Reactivation during
RituximabAdministration
Acute hepatitis caused by HBV is initially suppressed by
cytokines secreted from NK and other types of cells. CD8-
positive cells subsequently induce a CTL reaction which then
eventually leads to hepatitis. Since hepatitis is triggered by
CTLs, a time lag exists from initial infection to hepatitis
onset [38, 39]. However, hepatitis that arises from HBV
reactivation, unlike that which occurs during conventional
HBV infection, is under a state of immunosuppression2 Hepatitis Research and Treatment
of the normal immunological responses to HBV, leading
to increased viral replication and widespread infection
of hepatocytes. When immunosuppression is removed by
discontinuation of chemotherapy, immune competence is
restored and infected hepatocytes are rapidly destroyed,
leading to hepatitis. It is therefore likely that reactivated
HBV results in a shorter time period to hepatitis progression
than seen in conventional HBV infection. We believe that
this mechanism of hepatitis aggravation can explain those
case patients who die despite administration of lamivudine
in response to HBV reactivation during chemotherapy or
use of immunosuppressive drugs. In contrast, HCV tends
to become chronic through suppression of the induction
and ampliﬁcation of immune responses (such as interferons)
from the outset, and this may be why hepatitis caused by
HCV reactivation during the use of anticancer or immuno-
s u p p r e s s i v ed r u g si sl e s sl i k e l yt ob e c o m es e v e r e[ 40–42].
We have reported on reactivation of HBV and hepati-
tis during rituximab treatment alone or in combination
with chemotherapy. Other groups have reported a rate of
HBV reactivation of 20% ∼55% [15, 18–20]. One report
claims an HBV reactivation rate of 3%, even in HBsAg-
negative cases [43] .U m e m u r ae ta l .r e p o r t e da4 %r a t e
of HBV reactivation in HBsAg-positive patients based on
a questionnaire conducted in Japan, which is lower than
previous studies, and 20% of these patients developed fatal
hepatitis [44]. Frequent HBV reactivation is also thought to
occur as a complication of chemotherapy during treatment
of lymphomas and may be inﬂuenced by steroids [18,
45, 46]. Since the initial use of rituximab in the clinic,
debate has centered on whether rituximab alone can induce
HBV reactivation or whether it does so only when used in
combination with chemotherapy. Initially, we believed that
rituximab alone was unlikely to induce HBV reactivation
[21]. However, subsequent reports by us and by Yang et al.
have shown that HBV reactivation can occur with rituximab
alone, and it is therefore likely that rituximab itself can
induce HBV reactivation [22, 37]. Although reactivation of
HBV is deemed more likely when rituximab is combined
with chemotherapy or steroid therapy, clearly the use of
rituximab alone cannot be deemed completely safe [22].
Future prospective analyses are needed to deﬁnitively answer
whether or not reactivation of HBV is more prevalent
in patients given rituximab alone or given chemotherapy
without rituximab. Nonetheless, in a questionnaire survey at
a Hokkaido facility examining and treating blood diseases,
HBV reactivation cases were observed only in patients given
rituximab alone. These results support the study by Yeo et
al., showing that reactivation of HBV is more prevalent in
patientsgivenrituximabalonecomparedwithchemotherapy
alone [22, 47].
3. Risk Factors for HBV Reactivation
Todate,variousinvestigatorshaveidentiﬁedanumberofrisk
factors for HBV reactivation which include being male, HBs
antigen positivity, HBV-DNA level, presence of lymphoma,
use of anthracyclines or steroids, second- and third-line
anticancer drug treatment, and youth. A review of these
factors by Yeo et al. showed that youth, being male, and
liver function prior to chemotherapy were potential risk
factors. Furthermore, Yeo et al. conducted an analysis on
HBV reactivation in patients using rituximab, as there is a
potential for risk factors to change in such cases. Including
risk factors which had previously been reported, they list
being male, lacking HBs antibodies, and using rituximab as
additional risk factors. Further analyses on such risk factors
are needed in order to enable the stratiﬁcation of HBV-
infected patients receiving rituximab in order to identify
those that require preventive administration with nucleoside
analogs [20, 47, 48].
4.HBsAg-Positive,Anti-HBc-Positive,and
HBV-DNA-Positive Cases
In HBsAg-positive patients, there have been reports of
HBV reactivation during chemotherapy [8–20]. Increased
liver function and a tendency for increased jaundice and
lowered albumin have also been reported in hepatitis
cases caused by HBV reactivation, compared to primary
HBV infection [44]. Similarly, HBV reactivation has been
reported in patients receiving chemotherapy in addition to
rituximab [21–37]. For these patients, attempts to prevent
HBV reactivation are needed regardless of whether or not
rituximab is given. Preventive administration of nucleoside
analogs is currently recommended for such patients, and
chemotherapy under preventive administration is desirable
[49–63]. Although there are few complete reports of cases
in which rituximab was used in combination with pre-
ventive treatments, He et al. among others have suggested
the eﬀectiveness of preventive lamivudine [49, 64, 65].
Loomba et al. reported that preventive lamivudine therapy
reduced HBV-reactivation-related hepatitis by 79% or more,
based on an analysis of previous studies [49]. However, it
hasbeenreportedthatwithlamivudineadministration, drug
resistance increases yearly by 15%–20% [66, 67]. Thus, with
preventative administration of lamivudine, the emergence of
resistant HBV strains is highly problematic.
A report by Pelizzari et al. suggested that lamivudine
administration may result in a lower likelihood of emergent
drug resistance compared to treatments for conventional
hepatitis B [56]. However, Picardi et al. reported numerous
instances of HBV genome mutations in patients receiving
chemotherapy with ﬂudarabine [68]. In addition, they have
shown that there is a high risk of HBV resistance to
lamivudine in patients undergoing treatments that have
powerful immunosuppressive eﬀects. A similar report exists
for chemotherapy combined with rituximab, and it is
possible that similar occurrences may be observed when
steroids or ﬂudarabine are used together with rituximab
[69]. From these observations, as well as considering issues
of emergent drug resistance, administration of entecavir
is preferred over lamivudine for the prevention of HBV
reactivation.Additionally,evenamongHBsAg-positivecases,
preventive treatment may change in relation to the level
of HBV-DNA present. Various guidelines recommend that
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administration against HBV-DNA is necessary, the analog
should be changed to entecavir. In patients who have a
high level of HBV-DNA, it is desirable to use drugs such
as entecavir, based on its eﬀectiveness against the YMDD
mutation [70, 71]. Moreover, for HBsAg chronic hepatitis,
the guidelines recommend the use of entecavir when HBV-
DNA is more than 2000IU/ml, while lamivudine is adequate
at less than 2000IU/ml. In addition, in HBV-DNA-positive
cases, it may be necessary to screen for YMDD mutations
in advance as there is a possibility in these cases that other
treatments will be necessary, such as the use of tenofovir or
the combined use of 2 nucleoside analogs [70–73].
5.Anti-HBc-Positive,Anti-HBs-Negative,and
HBsAg-Negative Cases
Anti-HBc-positive cases indicate a prior history of HBV
infection. These include window period cases as well as
cases which are HBV-DNA positive and Anti-HBs negative
or HBsAg negative (occult HBV infection) [43, 74–76].
Caution is required in these cases when using rituximab,
chemotherapywithanticancerdrugs,orimmunosuppressive
drug preparations [70, 71]. Although rare, HBV reactiva-
tion during chemotherapy has been reported in Anti-HBs-
positive, Anti-HBc-positive cases or in cases positive only
for Anti-HBc [15, 26, 43, 45]. Moreover, in a study by
Hui et al., HBV reactivation-induced hepatitis was reported
in anti-HBc-positive, anti-HBs-negative cases, and even in
those that were HBV-DNA negative [43]. This shows that
hepatitiscausedbyHBVreactivationcanoccurinAnti-HBc-
positive cases regardless of HBV-DNA status. For these cases,
the guidelines recommend carefulmonitoring of HBV-DNA,
since hepatitis caused by HBV reactivation is uncommon
and treatment is expensive [70–73, 77]. Although reports
to date show that HBV reactivation in patients undergoing
chemotherapy is rare, when it does occur, the chemotherapy
treatment period is extended. In addition, the treatment
intensity of the chemotherapy against lymphoma declines,
and fatalities are not uncommon in HBV reactivation-
induced hepatitis. This is because the mortality of hepatitis
caused by HBV reactivation is about 30%–100%, and once
the disease is present, some patients are not able to be saved
[43–45]. Based on these facts, administration of nucleoside
analogs may be desired in these cases. It has been reported,
however, that HBV reactivation-related hepatitis can be
preventable by monitoring HBV-DNA level on a monthly
basis [43]. Further studies are needed, including calculations
of the cost involved in these treatments.
6.Anti-HBs-Positive,Anti-HBc-Positive,and
HBsAg-Negative Cases
HBV reactivation-induced hepatitis has been reported in
Anti-HBs-positive,Anti-HBc-positive,HBsAg-negativecases
[15, 26, 43, 45]. In addition, while rare, there have been
sporadic reports of cases in which HBV reactivation was
observed after administration of rituximab in patients that
were positive for Anti-HBs alone [29, 43, 78] although it is
generally thought that such occurrences are primarily due
to vaccine administration. Such cases may arise when, for
instance, the production of antibodies has declined with
age and only Anti-HBs remains; however, details from these
types of cases are unavailable. Caution is required, as even
in cases that are positive for Anti-HBs alone, the chance
exists that symptoms are due to HBV reactivation. In our
experience studying the changes in Anti-HBs after rituximab
administration, we have found that in the large majority
of cases, Anti-HBs antibody titers decreased with increased
number of rituximab administrations [21, 32, 33, 79].
Furthermore, we have experienced cases which presented
with HBV reactivation following an increase in HBV-DNA
that accompanied a decline in Anti-HBs and Anti-HBc
antibody titers [32, 33]. These results suggest an association
between Anti-HBs/Anti-HBc antibodies and HBV reactiva-
tion, and that monitoring these antibodies may provide an
index for HBV reactivation. In addition, regarding HBV
reactivation during bone marrow transplantation, Onozawa
et al. reported that a decrease in Anti-HBs titer results in
HBV reactivation-induced hepatitis [80]. As Anti-HBs is a
part of the humoral immune component which monitors
HBV, we surmise that transitions in Anti-HBs have the
potential to become indices for predicting hepatitis caused
by HBV reactivation. However, HBV reactivation has also
been observed by Westhoﬀ et al., in a patient with Anti-
HBs titers of 868mIU/mL, indicating that HBV reactivation
may occur even in cases with high Anti-HBs titers [26]. This
may indicate that predicting reactivation only by monitoring
Anti-HBs titers would be insuﬃcient.
7. Prevention of HBV Reactivation
From each group, treatment guidelines for prevention of
HBV reactivation are shown in Table 1 [70–73, 77]. From the
information detailed above, HBe-Ag- and HBsAg-positive
cases qualify as targets for preventive administration of
nucleoside analogs. In HBsAg-negative cases, it is likely
that the frequency of HBV reactivation in Anti-HBc only
positive cases is not necessarily high. However, since HBV
reactivation may lead to patient death, we believe that these
cases would qualify as targets for preventive administration
of nucleoside analogs. In contrast, in HBsAg-negative, Anti-
HBs-positive cases, it is desirable while observing changes in
antibody titers to additionally monitor HBV-DNA in those
cases with titers less than 500 [79]. Additionally, it is possible
that periodic monitoring of HBV-DNA may predict HBV
reactivation, and it is therefore advantageous, keeping cost
in mind, to combine these indices [81, 82]. Monitoring of
HBV-DNA is also likely to be essential in cases having HBV-
DNA mutations and in whom antibody expression is weak
[81]. It is crucial, however, to stratify groups into those
in whom preventive administration can be recommended,
since with HBV-DNA monitoring alone, the frequency of
HBV reactivation has been reported to be higher in those
given preventive administration of lamivudine compared to
controls [51]. When monitoring for HBV reactivation, it
is important to identify HBV reactivation at an early stage
using, in addition to HBV-DNA monitoring, a variety of4 Hepatitis Research and Treatment
Table 1: Treatment guideline methods during chemotherapy or
immunosuppressive drug therapy.
AASLD
Subject to preventive treatment if HBsAg positive or
Anti-HBc positive & HBV-DNA positive. If HBV-DNA is
less than 2000IU, or for shortened treatment (∼1 year),
lamivudine or telbivudine is desirable. If HBV-DNA is
more than 2000IU and long-term treatment is necessary,
entecavir or tenofovir is desirable. If HBV-DNA level
remains less than 2000IU 6 months after completion of
treatment, treatment is discontinued, otherwise treatment
continues (2009)
APASL There are no guidelines (2005)
EASL
HBsAg cases are subject to treatment and HBV-DNA is to
be measured in these cases although there is no deﬁned
value in which recommendation for treatment can be
made. Lamivudine is most commonly used, however, it is
best to be used in cases with low HBV-DNA or in
conditions where resistant strains are less likely to emerge.
In cases with high HBV-DNA or having a high risk of
resistance, entecavir is desirable. Careful followup for
HBV-DNA and liver function is necessary for
HBsAG-negative, Anti-HBc-positive, and
HBV-DNA-negative cases. Vaccination is recommended in
HBV-seronegative cases (2009)
JAPAN
Subject to nucleoside analog treatment if HBsAg positive
or if HBsAg negative and Anti-HBs or HBc positive plus
HBV-DNA positive. lf HBV-DNA is negative, HBV-DNA
is monitored monthly, and nucleoside analogs are
administered when HBV-DNA becomes positive.
Entecavir is recommended as the nucleoside analog. The
timing of termination of nucleoside analog treatment will
be determined in accordance to the treatment for Type B
chronic hepatitis if HBsAg is positive. If Anti-HBs or
Anti-HBc is positive, nucleoside analog is administered for
12 months after the completion of immunosuppressive
therapy or chemotherapy. During this time, nucleoside
analog treatment will be discontinued if HBV-DNA is
negative and ALT is normal. Patients are closely observed
for 12 months after treatment with nucleoside analogs
(2009)
Abbreviations; HBsAG = hepatitis B surface antigen. Anti-HBs = antibody
to HBsAg. Anti-HBc = antibody to hepatitis B core antigen. HBV-DNA =
hepatitis B virus DNA.
additional information including changes in anti-HB titers.
Kusumoto et al. summarized the risks of HBV reactivation
during chemotherapy in reference to HBsAg, Anti-HB, and
level of treatment. These data may be useful for preventive
treatment, however, more clinical studies are needed [83].
Preventive administration against HBV is recommended for
a period of 6 months following completion of treatment
[67, 70]. This may not be suﬃcient, however, as a number
of cases in which HBV reactivation occurred more than 4–
6 months after treatment have been reported [84–88]. The
6-month timeframe is possibly associated with changes in B-
cell number [1–3, 82, 88]. The guidelines proposed by Lok
and McMahon in 2007 have been more speciﬁc compared
to past guidelines and have incorporated recommendations
such as extending the period of preventive administration
depending on the HBV-DNA level [70]. We observed a case
in which HBV reactivation occurred 4 years after termi-
nation of preventive lamivudine administration following
completion of treatment [79]. From this case, we surmise
that for HBeAg- or HBsAg-positive cases in which Anti-HBs
cannot be produced, it is necessary to combine the use of
nucleoside analogs from the initial time of treatment and
to continue their use. In addition, for cases which are Anti-
HBs positive from the outset, we believe that preventive
administration of nucleoside analogs is necessary at least
until Anti-HBs titers return to pretreatment levels, and that
the period of nucleoside analog administration needs to be
determined using immune recovery, for example, of anti-
HBs, as an index. However, with long-term administration
of drugs such as lamivudine or entecavir, issues such as cost
arise; therefore, it is hoped that cases requiring long-term
preventive administration will become clariﬁed in the future
withfollowupstudies.Asthisreportshows,preventivenucle-
oside analog administration involves issues of lamivudine
resistance, therefore we believe it is desirable to administer
entecavir at an early stage. Although we commonly set
lamivudine dosing at 100mg and entecavir at 0.5mg, it
is recommended that entecavir be increased to 1mg when
dealing with lamivudine-resistant cases [70–73]. Compared
to lamivudine, resistance to entecavir is less likely to develop
[89], and administration of entecavir is recommended in
cases where preventive administration against HBV will
exceed 12 months [70, 71, 73]. In lamivudine-resistant cases,
some clinicians recommend the combined use of entecavir,
adefovir, or tenofovir with lamivudine [73] while others
recommend switching over completely [72]. We believe that
combined use with lamivudine is desirable, as it has been
reported that adefovir-resistant strains immediately develop
when patients with lamivudine-resistant strains are switched
over to adefovir alone [90]. In seronegative HBV cases that
are treated with immunosuppressive or anticancer drugs, the
use of HBV vaccine has been recommended [73]. However,
as mentioned previously, when using rituximab, anti-HBs
level decreases and then disappears, and it is therefore
possible that no antibodies will be produced after prior
administration of vaccine; therefore, it may be desirable to
administer vaccine after completion of treatment. In some
cases, however, hepatitis caused by HBV reactivation cannot
be controlled with a vaccine, and it is therefore possible
that HBV reactivation will not be prevented with vaccination
alone [78]. Future studies on vaccine eﬃcacy in patients
receiving rituximab or chemotherapy are needed; however,
it will take considerable time before practical applications of
these studies can be realized.
8. Conclusions
HBVreactivationduringchemotherapytreatmentisthought
to occur from HBV ampliﬁcation in hepatocytes as a
result of immunosuppression caused by anticancer drugs,
and subsequently from HBV-infected hepatocytes that are
targetedbyanimmune response thatbecomesactivatedafter
removal of this immunosuppression [45]. It is likely that one
of the causes of HBV ampliﬁcation during the combined
use of chemotherapy and rituximab is the reduction inHepatitis Research and Treatment 5
antibody titers that accompanies a decrease in B cells
[79, 91]. In addition, rituximab is able to alter the T
lymphocyte population, and it is possible that aggressiveness
toward HBV intensiﬁes as a result, further promoting HBV
ampliﬁcation and subsequent recovery of the distribution of
immunocompetent cells such as lymphocytes [92]. Uemura
et al. found that chemotherapy-induced reactivation of HBV
is more lethal compared to acute HBV hepatitis, and the
likelihood of survival also decreases; therefore, it is crucial
to prevent this method of disease onset [36, 44]. It is hoped
that future studies will further clarify the changes that occur
in immune functions of the organism during rituximab use
along with the mechanisms of HBV reactivation, which will
lead to safer and more eﬀective treatments for malignant
lymphomas.
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